I believe we have a unique opportunity to take this value proposition and serve constituents across the entire health care ecosystem, leveraging data and insights to better serve our core clients and create value across the broader ecosystem is fundamental to how we will complete our journey to becoming a world-class public company that delivers sustainable growth. In my first two months on the job, I've engaged with our associates, our clients, strategic industry partners and many provider health systems. These engagements have demonstrated the incredible integrity and professionalism of the MultiPlan team, reinforce my confidence in the potential of the company and validated my commitment to helping this company carry out its critical mission in the health care market, positioning MultiPlan for accelerated and sustainable growth begins with the devotion to business fundamentals that drive performance excellence.

Business success will come as we serve clients, understand the problems the market is trying to solve and create mechanisms to deliver value. I've taken two important initial steps that reinforce accountability and build upon our long-standing record of service excellence. First, I've established a core operational framework centered upon the principles of clarity, alignment and focus. Clarity of mission and purpose, alignment of accountability and leadership, focus on operational metrics that matter. To that end, we have established over 30 corporate key performance indicators to measure and manage the business proactively. You are what your record says you are and we will keep score and be accountable. Second, I am also focused on alignment of our talent.

MultiPlan has an exceptional leadership and management team with deep domain expense and dedication to our important mission. Combining that talent with new leadership and perspective will be an accelerant for us going forward. To ensure rigor discipline and operating cadence as we proceed have established a new Chief Operating Officer position that will report directly to me and I've already onboarded a new leader to fill this important role. Jerry Hogg joined MultiPlan on March 11th and has already begun a structured assessment of the organization and will lead the team that designs and defines the new MultiPlan operating model to enable and support our growth. Another key addition to my executive leadership team is my Chief of Staff, Jackie Kwan, who along with our Chief Operating Officer will drive our key performance indicators and deliver timely management reporting that will enable real-time course adjustments as we manage the business.

This will enable us to drive top-line growth while proactively managing bottom-line performance with predictability. Jerry and Jackie both have extensive experience in publicly run, product-focused growth companies. This will be invaluable to us as we proceed. In addition, given the revenue growth potential of our existing product portfolio, we added three new senior sales leaders to our team, each of whom have deep experience and relationships in key adjacent markets. The expansion of our sales team demonstrates our commitment to investing in growth and our intent to compete more aggressively in all of our market segments. Furthermore, we are also focused on what we call Fit for Growth, which includes initiatives like product lifecycle management, data science, data platform development, and process automation.

These initiatives will support accelerated growth that we will achieve with strategic enhancements to existing products for our core business and by introducing new, innovative products to expand the value we provide to adjacent and new vertical markets. This framework of clarity and alignment focus, talent, and fit for growth will enable us to sharpen our focus on our horizons for growth, which include the following. Horizon 1, or what I call the now, delivering on our 2023 and 2024 product roadmap, attacking competition and target markets and driving value into our core client base. As you see on Page 9, we are progressing on schedule with our product development roadmap, and I'm encouraged with our focus on achieving our milestones. Horizon 2, or what I call near, is accelerating the evolution of organic product development while bringing to market new data and decision science products with insights to serve clients across the healthcare continuum.

We are doing market and partner research now. I'm excited to continue to update you on that as we progress with more to come. Horizon 3, or what I call next, a world-class product company strategically positioned to take advantage of licensed software, platform products, and data assets across multiple market segments as healthcare evolves. We will do all of this while continuing to manage our financial position, repay our debt, and prudently allocate our capital. This will be a multi-year journey, but I believe we are well-positioned for the future and will complete our transformation to a company that has diverse product set, strong organic revenue growth and fortified business and financial models. Turning to the quarter, we had several notable successes.

First, we received a positive 73 net promoter score across all of our clients, which is 25% higher than the prior year and in the top quartile of the global benchmark, demonstrating our value proposition to our clients and our dedication to service and operational excellence. We will continue to earn that reputation and our clients' trust every day. Second, we increased our sales pipeline and closed 73 opportunities, representing a 36% year-over-year increase in new sales. Third, we signed four new logos with HST's value-driven health plans, and we've made progress going to market through our HST platform to sell our new balance bill protection product. Fourth, we closed our first plan optics sale in the first quarter, and our pipeline of plan optics business is gaining momentum.

Platform transparency products and predictive analytics will be an important part of our future, and we are beginning to see our efforts converting in the market. Fifth, we closed our sale for auto pay and our supplemental carrier products. And finally, with regard to strategic partnerships, we are expanding and deepening our conversations with potential partners about how we can work together on promising new growth opportunities, which I plan to tell you more about in the coming quarters. From a financial point of view, our quarter was impacted by a cybersecurity incident at a major medical claims clearinghouse, which disrupted claims flow across healthcare and ultimately downstream to our platform. Despite this disruption, first quarter revenues were $234.5 million, and first quarter adjusted EBITDA was $146.8 million, both slightly below the low end of our guidance range.

Excluding the disruption in claims flow, which we estimate to be $5 to $6 million of revenue in the quarter, our first quarter results would have been in line with our guidance. During the quarter, we generated free cash flow and reduced the face value of our debt by over $24 million. Despite dealing with several exogenous events, it was a solid quarter, and we made material progress on key priorities. Looking forward, we expect our second quarter results to show improvement over our first quarter. And based on what we know today, we are affirming our FY 2024 guidance at this time, as Jim will discuss in a moment. Before I turn it over to Jim to review the financial results for the quarter in more detail, I want to make a few additional comments.

I am pleased with the performance of the team as we navigated several notable external events in the healthcare market. Every challenge presents an opportunity and we were able to pull together quickly as a management team and respond as a unit. The team and company remain focused on delivering value and service to our clients. We will not be distracted by extraneous noise or uncontrollable events from the supported mission in health care. It's been an exciting rewarding two months on the job. I want to reiterate that 1 of the most important reasons I came to MultiPlan was my belief in the mission of the company and the integrity and dedication of our associates to that mission. MultiPlan has been bringing affordability, efficiency and fairness to US healthcare for over 40 years.

This includes over 1.4 million providers that we contract with directly through our network today and we work with those providers and many others daily to ensure that they are compensated for their critical services with accurate and swift reimbursements using our solutions to minimize friction. I had the pleasure of serving providers for 22 years, and I still do. I wouldn't have come to MultiPlan if I didn't believe we provide an important service for all the constituents of healthcare. We will continue to serve our mission by bringing data, analytics and innovation in an objective manner to the healthcare industry to reduce cost and administrative burden for all eliminate balance bills and lower out-of-pocket expenses for millions of healthcare patients.

It is my firm belief that there is enormous potential value yet to be realized as we expand our clients, our product offerings and bend the cost curve in healthcare. I will now turn it over to Jim.

Jim Head: Thanks, Travis, and good morning, everyone. I would like to begin by echoing Travis' comments. We're excited about carrying our strategy forward with the new members of our management team. The executive transition has been smooth. We've made several pragmatic changes to our operating model that will accelerate our progress. We successfully navigated a difficult industry-wide challenge and the company is energized. Today, I will walk through the financial results for the first quarter of 2024. I'll then turn to our outlook for Q2, and I'll close with a review of our balance sheet and update on our capital allocation activities. As shown on page 4 of the supplemental deck, first quarter revenue was $234.5 million, a decrease of 0.9% from Q1 2023 and a decrease of 3.9% sequentially.

Our revenues fell just shy of the low end of our guidance range for the quarter despite the disruption to our claims volumes caused by the clearinghouse cyber outage that Travis mentioned previously. While it's difficult to quantify precisely, we estimate this disruption impacted our first quarter revenues by roughly $5 million to $6 million. And excluding this impact, our revenues would have been within our guidance range for the quarter. Turning to revenues by service line, as shown on page 5 of the supplemental deck. Relative to Q4 2023, network-based revenues declined 11.6% sequentially or $6 million driven largely by the impact of the aforementioned claims volume disruption to our complementary network, fee-for-service and property casualty businesses.

Also impacting the service line were a non-recurring customer credit and some client attrition. Our analytics-based revenues fell 2.1% sequentially, largely due to the claims volume disruption. Our Payment and Revenue Integrity revenues declined 0.6% sequentially also reflecting the impact of the clearinghouse outage on claims volumes for our prepaid solutions, offset by strength in our Discovery Health postpay solutions. Versus the prior year quarter, network-based revenues declined 19.3%; analytics-based revenues grew 5.0%; and Payment and Revenue Integrity revenues grew 4.8%. Excluding a $3.8 million contribution to revenues from BST, which is reported in our analytics-based revenues, first quarter consolidated revenues were $230.7 million, down 3.9% sequentially and down 2.4% from the prior year quarter.

Our first quarter results reflected volatility in claims volumes with the clearinghouse cyber outage impacting our claims flows, particularly in March, given our typical claim lag relative to dates of medical service. As shown on page 7 of the supplemental deck, total first quarter bill charges decreased 4% sequentially to $41.5 billion and identified potential savings decreased 3% sequentially to $5.7 billion. In our core commercial health plan segment, bill charges decreased 6% sequentially to $18.3 billion and identified potential savings decreased 3% sequentially to $5.4 billion. The sequential decreases were more acute in physicians claims compared to facilities-based claims. We believe the larger hospital systems were able to quickly switch to alternative clearinghouses or find other workarounds to route claims to payers.

Although the clearinghouse outage continued to affect our April volumes and we haven't digested the full impact given our claims lag, we continue to believe this is largely a timing issue, as our cost containment solutions are still required for claims coming through the payers. In terms of the utilization environment, we note the relatively strong first quarter facility volume data reported by the public [Technical Difficulty] operators who were able to work around the clearinghouse disruption by the end of the first quarter. The largely exogenous weakness in our volumes was exacerbated by a decline in revenues as a percentage of identified savings, on what we call revenue yield. As shown on page 8 of the supplemental deck, our revenue yield declined about four basis points sequentially for the overall business, which includes PSAV and PEPM.

In our core percentage of savings revenue model which is approximately 90% of our revenues, our revenue yield fell about 10 basis points in the quarter which had an impact of about $4.4 million to our revenues. That included about five basis points of decline from idiosyncratic yield shifts most of which are temporary and likely to abate and about five basis points of decline from a customer credit that we expect to run off in Q2. Importantly, none of the decline in our PSAV revenue yield was related to any contract changes with our customers. Turning to expenses. First quarter adjusted EBITDA expenses were $87.7 million, increasing $7.4 million from the prior year quarter, but up only $0.4 million sequentially. The increase of $7.4 million over Q1 2023 was driven by the combination of the acquisition of BST, structural cost increases and investments in the business year-over-year.

For the sequential comparison, the modest increase in adjusted EBITDA expenses reflected tight expense controls as we held the line on expenses amid the external pressures on our revenue. Adjusted EBITDA was $146.8 million in Q1 2024 down 6.1% from $156.3 million in the prior year quarter and down 6.4% from $156.8 million in Q4 2023. Our Q1 adjusted EBITDA was 2% below the lower end of our guidance due to the external pressures on our revenue. Adjusted EBITDA margin declined to 62.6% in Q1 2024 down 180 basis points from 64.2% in the prior quarter and down from 66% from the prior year quarter. Our first quarter margin was driven largely by the combination of lower revenues against our largely fixed expense base. As the volume environment normalizes, we expect our margins to track back to a 63% to 64% range in line with our prior commentary.

Turning to our second quarter guidance as outlined on page 11 of the supplemental deck. We anticipate revenues of $235 million to $250 million and adjusted EBITDA of $145 million to $160 million. Our second quarter projections reflect slightly lower visibility related to the ongoing and uncertain impact of the clearinghouse outage on our claims volumes. Our view is that the claims volume disruption is largely a timing issue and we began to see signs of that our volumes were normalizing in the back half of April. So despite the shortfall in our Q1 results and our lower visibility for Q2, our expectation is that revenue growth will accelerate in the second half and we are maintaining our guidance for fiscal year 2024. As you're aware from our press release based on the recent performance of our stock price, we conducted an impairment test in the first quarter of 2024 which incorporates current financial market conditions including our share price, market discount rates and other factors.

Based on this test the estimated fair values of our goodwill and indefinite-lived assets were less than their carrying values. As a result, we recorded non-cash impairment charges of $516.4 million for our goodwill and $2.7 million for our intangibles and recognized the charge in our GAAP earnings results. To clarify, the impairment charge was not driven by changes in our outlook for the business or our cash flow projections, but instead by our stock price and implied cost of capital. Turning to the balance sheet and capital allocation. Our operating cash flow was $49.7 million in the first quarter and levered free cash flow was $19.2 million. As a reminder, the first and third quarters are typically our higher quarters for cash flow given the timing of our interest and tax payments.

As shown on Page 14 of the supplemental deck, we ended the quarter with $59 million of unrestricted cash. Net of cash, our total and operating leverage ratios were 7.4x and 5.4x respectively. We continue to be disciplined in allocating our capital with a near-term focus on debt reduction. As shown on Page 12 of the supplemental deck, during the first quarter, we used $18.2 million of our cash to repurchase or repay $24.4 million face value of our debt, including $21.1 million face value of our 6% senior convertible PIK notes. We also allocated $10.5 million of our cash towards the repurchase of 11 million shares in the quarter. Our long-term capital priorities remain the same. Our highest priority remains investing in the business to drive growth and long-term value.

You should expect us to continue making a series of small, but critical organic investments to support our platform, including our new core products and our Data & Decision Science service line. With our remaining cash flow, we will primarily focus on debt reduction. While our long-term priorities have not changed, following the acquisition of BST, in the near term we will emphasize organic investments and debt reduction and deemphasize M&A. Finally, as I mentioned we spent $10.5 million on share repurchases in the first quarter. Additional share repurchases will not be a priority for the remainder of the year as we will focus on debt retirement. Before I end, I want to reinforce Travis' comments regarding the value of MultiPlan provides to the entire health care ecosystem.

We serve a critical role as a long-standing data-enabled intermediary between providers, payers, employers and consumers. We provide widely accepted services that reduce health care costs including for patients and make health care transactions more efficient, transparent and fair for all parties involved including 1.4 million providers over 700 payers over 100,000 employer plan sponsors and tens of millions of consumers. In 2023, we identified $23 billion in potential medical cost savings across all of our products and we reduced out-of-pocket costs and reduced or eliminated millions of balanced bills. Consider a few facts. In 2023, we priced $15.4 million out-of-network claims through our platform, $15.4 million. This service solves a significant problem for all parties involved, because there is no contracted price between providers and payers for out-of-network services.

And there is often a wide gap between the provider's list price and what employers are willing to pay for out-of-network services under their benefit plan designs. Our platform sits between these parties and serves a valuable role in helping to determine a fair price which in the case of MultiPlan and our services is accepted without appeal by providers 98% of the time. That's 98%. Further, it is widely known and transparent throughout the industry that out-of-network reimbursements are consistently priced at a premium to contracted in-network rates for the same service even after cost containment tools like ours are applied. By the way our average revenue per claim across our out-of-network pricing services in 2023 $44 per claim. That's $44.

Further, our services insulate millions of health care patients from balanced bills annually. In 2023, MultiPlan priced over 15 million out-of-network claims that were accepted without appeal or dispute including over 10.5 million claims for which we contractually eliminated balance bills for patients through our provider, network negotiation and surprise bill services. Nearly everyone agrees that the No Surprises Act was good for consumers. And in 2023, the number of balance bills we eliminated was approximately equivalent to the number eliminated by the No Surprises Act according to a recent survey conducted by AHIP and the Blues Association. And importantly, we didn't just start eliminating balance bills on behalf of consumers in 2022. When the No Surprises Act went into effect, we have been solving this problem for decades.

That brings me to the end of my comments. I'll turn the call back over to Travis.

Travis Dalton: Thank you, Jim. Let me say a few closing words before I open up the call to questions. As I said earlier, it's been an exciting and interesting first two months on the job. As I mentioned, the experience has strengthened my conviction about the value and potential of this company. I will also note that it has not been without challenges. I'd like to think of myself as realistic but optimistic and every challenge creates opportunity, as I've noted. The reality is that it has been a difficult moment as we contended with a number of external pressures including macro uncertainty in healthcare as well as some company-specific adversity that was largely out of our control. I believe we should take the challenges head on and stay focused on our clients and the markets that we serve.

Optimistically, these challenges have posed an extraordinary opportunity for our management team and associates to band together, sharpen our point of view and develop as a team. I also see tremendous opportunity for the company to execute better and evolve overtime across the healthcare continuum. I'm confident that as we continue to enhance our foundation and quicken our execution velocity, we will realize our transformation to a world-class company. Would you kindly open the call for questions? Thank you.

See also

Best English-Learning Courses Online: 10 Free or Cheap Alternatives and

25 Richest Billionaires in Metals and Mining Industry.

To continue reading the Q&A session, please click here.